Skip to main content
Entheon Biomedical Corp. logo

Entheon Biomedical Corp. — Investor Relations & Filings

Ticker · ENBI ISIN · CA29383X2023 LEI · 894500N2J7IXCCDRWU50 CSE Professional, scientific and technical activities
Open in API
Filings indexed 243 across all filing types
Latest filing 2024-03-26 Regulatory Filings
Country CA Canada
Listing CSE ENBI

About Entheon Biomedical Corp.

https://www.entheonbiomedical.com/

Entheon Biomedical Corp. is a biotechnology research and development company focused on creating therapeutic solutions for addiction and substance use disorders. The company specializes in the development and commercialization of psychedelic medicines, particularly dimethyltryptamine (DMT). Entheon aims to progress psychedelics to therapeutics by engineering proprietary drug discovery platforms, innovative drug delivery systems, and novel compounds tailored for treating these complex conditions.

Recent filings

Filing Released Lang Actions
AB form 13-501F1 (class 1 and 3B reporting issuers - participation fee).PDF
Regulatory Filings Classification · 100% confidence The document is a Form 13-501F1 titled 'Class 1 Reporting Issuers and Class 3B Reporting Issuers – Participation Fee' submitted to the Alberta Securities Commission. It includes a management certification by an officer of the reporting issuer, certifying the completeness and accuracy of the information. The content focuses on market value calculations for specified trading periods, capitalization, and participation fee details. There are no financial statements, earnings data, or detailed management discussion. The document is primarily a regulatory filing with certification and fee calculation information, not a full financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS).
2024-03-26 English
ON form 13-502F1 (class 1 and 3B reporting issuers - participation fee).PDF
Regulatory Filings Classification · 95% confidence The document is titled 'FORM 13-502F1' and is a 'Management Certification' submitted to the Ontario Securities Commission. It includes detailed calculations of market value of equity securities for quarterly periods, participation fees, and certification by a corporate secretary. The content is primarily a regulatory filing form related to fees payable by a reporting issuer, with no financial statements or management discussion of results. It is a certification and fee calculation form submitted to a regulatory body, not a financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS). The document length is about 5,322 characters, which is consistent with a detailed regulatory form rather than a brief announcement or a full annual/interim report.
2024-03-26 English
Audited annual financial statements – English.pdf
Annual Report Classification · 100% confidence The document is titled 'Consolidated Financial Statements for the Years Ended November 30, 2023 and 2022' and includes an Independent Auditors' Report. It contains detailed financial statements such as the consolidated statements of financial position, comprehensive loss, changes in equity, and cash flows. The audit opinion is provided by Chartered Professional Accountants, and the report discusses accounting policies, going concern, and audit responsibilities. The content is comprehensive and includes actual financial data and analysis for a full fiscal year, consistent with an annual report. There is no indication that this is merely an announcement or a certification letter. Therefore, this document is best classified as an Annual Report (10-K equivalent).
2024-03-26 English
Notice of meeting - English.pdf
AGM Information Classification · 100% confidence The document is a Notice of Annual General Meeting (AGM) for Entheon Biomedical Corp. It announces the date, time, and agenda of the AGM, including receiving audited financial statements, electing directors, appointing auditors, and other business. It provides details on how shareholders can attend and vote, including proxy instructions. The document does not contain the actual financial statements or detailed report content but is an announcement of the meeting and its agenda. The document length is short (2189 characters), consistent with a notice rather than a full report. Therefore, it fits the category of AGM Information (AGM-R).
2023-12-04 English
Form of proxy - English.pdf
AGM Information Classification · 100% confidence The document is a Form of Proxy for the Annual General Meeting (AGM) of Entheon Biomedical Corp. It includes instructions for appointing a proxy to vote on behalf of shareholders at the AGM, details on voting methods, and management voting recommendations. It does not contain financial statements or detailed report content but is clearly related to the AGM process. Therefore, it fits the category of AGM Information (AGM-R). The document length and content confirm it is not merely an announcement but the proxy form itself, supporting the AGM-R classification.
2023-12-04 English
Management information circular - English.pdf
AGM Information Classification · 100% confidence The document is titled 'INFORMATION CIRCULAR FOR THE 2023 ANNUAL GENERAL MEETING' and contains detailed proxy solicitation information, voting procedures, record dates, and instructions for shareholders to vote at the AGM. It is clearly a circular sent to shareholders in advance of the Annual General Meeting, providing information necessary for voting and proxy appointment. It is not the actual AGM presentation or minutes, nor is it an announcement of voting results. It is not a financial report or earnings release. Therefore, this document fits the definition of AGM Information (AGM-R), which includes presentations and materials shared during the AGM process, including proxy solicitation materials and information circulars.
2023-12-04 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.